Neuralink N1 Implant: Status, Studies, and Evidence

Neuralink N1 Implant Product Profile

The Neuralink N1 Implant is an investigational, implanted brain-computer interface being studied for external-device control and other research uses. It is not an approved consumer product or an ordinary medical treatment.

The current evidence comes from clinical-trial registry records, regulator guidance, sponsor materials, and participant reports. Each source answers a different question.

flowchart TD
    A["Neural activity"] --> B["N1 Implant records signals"]
    B --> C["Wireless data transfer"]
    C --> D["BCI software decodes intent"]
    D --> E["External-device action"]
    F["R1 Robot"] --> A
    G["Clinical study controls"] --> B

Product record

This record was checked on July 28, 2026. Device design, study status, eligibility, sites, outcomes, results, and regulatory state can change.

What the system is designed to do

The ClinicalTrials.gov PRIME record describes N1 as a skull-mounted, wireless, rechargeable implant connected to electrode threads. The R1 Robot places the threads in the brain. The system records neural signals associated with movement intention so that software can support control of an external device.

Neuralink's device-control page currently describes PRIME research involving computers and CONVOY research involving an assistive robotic arm. The same page calls N1 investigational.

The device should be described through the purpose of the specific study. PRIME does not establish restored walking, broad treatment of paralysis, general robotic control, or routine availability. CONVOY is a separate investigational study and should not be used to rewrite the 2024 PRIME evidence state.

What investigational means

Neuralink says PRIME proceeds under an FDA investigational device exemption. The FDA explains that an IDE allows an investigational device to be used in a clinical study to collect safety and effectiveness data.

The pathway includes applicable institutional review, informed consent, monitoring, labeling, records, and reporting. It does not grant marketing approval. It does not establish that a device is safe and effective for routine use.

This distinction is easy to lose when a participant demonstration resembles a product launch. The study exists because important questions remain open.

What participant reports establish

Neuralink's May 2024 progress update describes Noland Arbaugh using the system to control a laptop, play games, browse, and use applications. Arbaugh described practical value in being able to use a computer from bed and with less caregiver setup.

That first-person account is relevant evidence about one participant's experience. Neuralink also reported that some threads retracted, reducing the number of effective electrodes and measured cursor performance. The company said software and interface changes later improved performance.

The thread disclosure belongs in the same record as the successful use. It shows why device performance, tissue interaction, software response, duration, and follow-up cannot be reduced to one clip.

Neuralink's second-participant update describes another participant's computer and design-software use and the company's mitigation claims. It remains a sponsor report, not posted study results.

What remains unknown

The public PRIME record currently shows no posted results. That means the registry does not yet provide a completed results section for the study.

Sponsor stories do not establish general safety, effectiveness, durability, benefit, or suitability. The evidence still needs the study's full participant record, outcomes, adverse-event analysis, follow-up, protocol context, and appropriate review.

An estimated primary-completion date is not proof that analysis is complete. A participant count reported across Neuralink programs is not the same as enrollment or results for PRIME.

Privacy, support, and continuity

An implanted BCI can involve neural signals, health information, telemetry, software activity, charging, calibration, updates, and research-session records. A complete product record should identify the applicable data controls, support model, maintenance requirements, update policy, incident path, and consequences of degraded performance.

Those details also affect accessibility and independence. A system can reduce one support burden while creating another through charging, calibration, research sessions, software compatibility, or specialist service.

The user's experience and priorities should remain visible. A vendor, caregiver, employer, or commentator should not define benefit alone.

Venture Step context

E010 was recorded after Arbaugh's first public demonstration. The corrected package treats his experience as meaningful without turning it into a general clinical outcome.

Read [[Neuralink PRIME Study Research Profile]] for the registry-level study record and [[Neuralink Company Profile]] for sponsor identity. [[Robotics and Neurotechnology Need Evidence Consent and Safeguards]] explains the wider evidence and agency requirements.

This product profile was developed with AI assistance from the preserved E010 transcript and the linked ClinicalTrials.gov, FDA, and Neuralink sources. It does not provide medical advice, trial advice, or an assessment of any person's eligibility or treatment options. Clinical, regulatory, device, safety, privacy, accessibility, and ethics review remain required. Publication is unauthorized.